论文部分内容阅读
目的探讨不同抗结核方案对慢性HBsAg携带患者肝功能的影响和疗效。方法将确诊的乙肝大三阳,肝功能正常的慢性HBsAg携带合并肺结核患者105例按不同的治疗方案分成A[2HRZS(E)/4HR]、B[2HLSE/10HLE]、C[3LSE/9LE]3组,比较不同组别的肝功能受损率和近期疗效。结果A组38例,肝功能受损率47%;B组40例,肝功能受损率20%;C组27例,肝功能受损率3%。A组肝功能受损率明显高于B、C组(P<0.01);B组高于C组(P<0.01),3组间近期疗效差异无显著性(P>0.05)。结论使用含R、H方案抗结核治疗,其肝功能受损率明显增高,而用3LSE/9LF方案者肝功能受损率小。3组间近期疗效差异无显著性,临床上在抗结核药物的选择上应根据情况慎用。
Objective To investigate the effect and curative effect of different anti-TB regimens on liver function in patients with chronic HBsAg. Methods 105 cases of chronic HBsAg-positive pulmonary tuberculosis patients with chronic hepatitis B were divided into A [2HRZS (E) / 4HR], B [2HLSE / 10HLE] and C [3LSE / 9LE] according to different treatment regimens. 3 groups, compared the different groups of liver function damage and short-term efficacy. Results 38 cases of group A had a liver function damage rate of 47%. Group B had 40 cases of liver function damage rate of 20%. Group C had 27 cases of liver function damage rate of 3%. The damage of liver function in group A was significantly higher than that in group B and C (P <0.01), while that in group B was higher than that in group C (P <0.01). There was no significant difference between the three groups in the short term efficacy (P> 0.05). Conclusions The anti-TB therapy with R, H regimen has a markedly impaired hepatic function, while the 3LSE / 9LF regimen has a low rate of liver dysfunction. No significant difference in the short-term efficacy between the three groups, clinically in the choice of anti-TB drugs should be used with caution under the circumstances.